News 
Market Data 
Discover
Replies to post #182663 on Anavex Life Sciences Corp (AVXL)
Further interesting note, I did not know this:
In 2016, 3-71 was granted FDA Orphan Drug Designation for treatment of Frontotemporal Dementia.
Note: the FDA designation runs for 7 years. Anavex will need to use this advantage within the next 3-4 years.
https://www.anavex.com/u-s-fda-grants-orphan-drug-designation-to-anavex-3-71-for-the-treatment-of-frontotemporal-dementia/
Additionally, from cite 2 above Parkinson’s News 4/17:
Dr. Helene Hall, Professor at McGill:
“Anavex 3-71 also decreased the accumulation of amyloid beta protein and reversed cognitive deficits in mice with Alzheimer’s. The reversal occurred despite the mice having an advanced stage of the disease. [Bold, underline]
Same source:
Importantly, the results held after the body eliminated Anavex 3-71, a finding that appears to strengthen its therapeutic potential.” [Bold, underline]
Back to me. My commentary: It appears 3-71 is much more potent than 2-73, but is more specific to dementias which is smaller market.
Perhaps this would answer some questions as to why A2-73 was brought out earlier. (Potential size of indications) Note to BaltimoreBullet, if reading.
This research was done in 2017. Until then, we didn’t know what we didn’t know...which was Peyton Manning and which was Tom Brady, but both very good. I speculate we went with potential market size - it’s tough to beat Manning and those Nationwide commercials, for large endorsement dollars.../joke
Additionally, was VERY good news to hear that 3-71 showed reversal even in more severe cases of AD, and approached from the synaptic loss, and was able to combat tau. All this even in small doses.
Perhaps, a 2-73, 3-71 combo someday will prove as formidable as Manning/Brady roster?
AI
